Citizens analyst Silvan Tuerkcan notes Intellia announced the FDA lifted the nexiguran ziclumeran hold on the ATTRv-PN side, while engagement is still ongoing on the CM side. The firm views this as a first positive sign of the program getting back on track. Citizens reiterates an Outperform and $21 price target on the shares, which is solely based on HAE. The firm continues to see a valuation disconnect between the market cap and the HAE opportunity alone. Nex-z having a path back into the clinic should add significant value, Citizens adds.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial
- Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study
- FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial
- Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 trial